Norris Perne & French LLP Galectin Therapeutics Inc Call Options Transaction History
Norris Perne & French LLP
- $1.3 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GALT
# of Institutions
109Shares Held
9.91MCall Options Held
2.47MPut Options Held
4.47M-
Vanguard Group Inc Valley Forge, PA2.14MShares$3.01 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$2.2 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$1.67 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA871KShares$1.23 Million0.0% of portfolio
-
Wealthspire Advisors, LLC New York, NY398KShares$561,7070.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $83.8M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...